Attached files
| file | filename |
|---|---|
| 8-K - Statera Biopharma, Inc. | v226520_8k.htm |
| EX-99.1 - Statera Biopharma, Inc. | v226520_ex99-1.htm |
| EX-10.1 - Statera Biopharma, Inc. | v226520_ex10-1.htm |
| EX-10.2 - Statera Biopharma, Inc. | v226520_ex10-2.htm |
EXHIBIT 5.1
 |
Chrysler Center
666 Third Avenue
New York, NY 10017
212-935-3000
212-983-3115 fax
www.mintz.com
|
June 21, 2011
Cleveland BioLabs, Inc.
73 High Street
Buffalo, New York 14203
Ladies and Gentlemen:
This opinion is furnished to you in connection with a Prospectus Supplement, dated June 17, 2011 (the “Prospectus Supplement”), to a Registration Statement on Form S-3 (File No. 333-167258) (the “Registration Statement”) filed by Cleveland BioLabs, Inc. (the “Company”) with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities Act”), relating to the sale of 5,872,500 units in a “registered direct” offering (the “Offering”) at a purchase price of $4.00 per unit (each, a “Unit”). Each Unit consists of (i) one share of the Company’s common stock, par value $0.005 per share (the “Common Stock”), (ii) one warrant to purchase 0.25 of one share of Common Stock, with an exercise price of $4.50 per share (a “Series E Warrant”) and (iii) one warrant to purchase 0.25 of one share of Common Stock, with an exercise price of $5.00 per share (a “Series F Warrant” and, together with the Series E Warrant, the “Warrants”). The Common Stock issuable upon exercise of the Warrants are referred to herein as the “Warrant Shares” and the Common Stock and the Warrants (together with the Warrant Shares) sold in the Offering are collectively referred to herein as the “Securities”. The Securities were sold pursuant to an engagement agreement (the “Engagement Agreement”) by and between the Company and Rodman & Renshaw, LLC, as placement agent, dated June 16, 2011, and the securities purchase agreements between the Company and the purchasers of the Units, each dated June 17, 2011 (each, a “Securities Purchase Agreement,” and collectively, the “Securities Purchase Agreements”). The Engagement Agreement, the form of the Securities Purchase Agreements and the form of Warrants have been filed as exhibits 10.1, 10.2 and 4.1, respectively, to a Current Report on Form 8-K, as filed with the Commission on the date hereof.
In connection with this opinion, we have examined and relied upon the Company’s Restated Certificate of Incorporation and the Company’s Second Amended and Restated Bylaws, each as amended to date and as currently in effect; the minutes of all pertinent meetings of directors of the Company relating to the Registration Statement, the Prospectus Supplement and the transactions contemplated thereby; such other records of the corporate proceedings of the Company and certificates of the Company’s officers as we deemed relevant for the purposes of rendering the opinions set forth in this letter; the Registration Statement and the exhibits filed thereto with the Commission; the Prospectus Supplement; the Engagement Agreement; the Securities Purchase Agreements; and the Warrants.
In our examination, we have assumed: (i) the authenticity of original documents and the genuineness of all signatures; (ii) the conformity to the originals of all documents submitted to us as copies; (iii) the truth, accuracy and completeness of the information, representations and warranties contained in the records, documents, instruments and certificates we have reviewed; (iv) the legal capacity of natural persons; and (v) the due execution and delivery of all documents, where due execution and delivery are a prerequisite to the effectiveness thereof.
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
New York | Washington | Boston | Stamford | Los Angeles | Palo Alto | San Diego | London
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
Based upon the foregoing, and subject to the limitations set forth below, we are of the opinion that: (i) the Common Stock, when issued by the Company and delivered by the Company against payment therefor as contemplated by the Securities Purchase Agreements, will be duly and validly issued, fully paid and non-assessable; (ii) the Warrants are duly authorized, and when duly executed and delivered by the Company in accordance with the Securities Purchase Agreements, will constitute the valid and binding obligation of the Company, enforceable against the Company in accordance with their terms; and (iii) the Warrant Shares, when issued by the Company and delivered by the Company against payment therefor as contemplated by the Warrants, will be duly and validly issued, fully paid and non-assessable.
Our opinion that any document is legal, valid and binding is qualified as to:
(a) limitations imposed by bankruptcy, insolvency, reorganization, arrangement, fraudulent conveyance, moratorium or other laws relating to or affecting the rights of creditors generally;
(b) rights to indemnification and contribution, which may be limited by applicable law or equitable principles; and
(c) general principles of equity, including without limitation concepts of materiality, reasonableness, good faith and fair dealing, and the possible unavailability of specific performance or injunctive relief and limitation of rights of acceleration, regardless of whether such enforceability is considered in a proceeding in equity or at law.
Our opinions are limited to the laws of the State of New York, the General Corporation Laws of the State of Delaware (including the applicable provisions of the Delaware Constitution and the reported judicial decisions interpreting such laws) and the United States federal laws, and we express no opinion with respect to the laws of any other jurisdiction. No opinion is expressed herein with respect to the qualification of the Common Stock under the securities or blue sky laws of any state or any foreign jurisdiction. To the extent that any applicable document is stated to be governed by the laws of another jurisdiction, we have assumed, for purposes of this opinion letter, that the laws of such jurisdiction are identical to the state laws of the State of New York.
Please note that we are opining only as to the matters expressly set forth herein, and no opinion should be inferred as to any other matters. This opinion letter is based upon currently existing statutes, rules, regulations and judicial decisions, and we disclaim any obligation to advise you of any change in any of these sources of law or subsequent legal or factual developments which might affect any matters or opinions set forth herein.
We hereby consent to the filing of this opinion in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act with the Commission as an exhibit to the Current Report on Form 8-K to be filed by the Company in connection with the issue and sale of the Securities and to the use of our name in the above-referenced Prospectus Supplement under the caption “Legal Matters.” In giving such consent, we do not hereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission.
|
Very truly yours,
/s/ Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
|